JP5224536B2 - 尿路系腫瘍の判定システム - Google Patents
尿路系腫瘍の判定システム Download PDFInfo
- Publication number
- JP5224536B2 JP5224536B2 JP2009129695A JP2009129695A JP5224536B2 JP 5224536 B2 JP5224536 B2 JP 5224536B2 JP 2009129695 A JP2009129695 A JP 2009129695A JP 2009129695 A JP2009129695 A JP 2009129695A JP 5224536 B2 JP5224536 B2 JP 5224536B2
- Authority
- JP
- Japan
- Prior art keywords
- coproporphyrin
- urine sample
- urinary tract
- present
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000029584 urinary system neoplasm Diseases 0.000 title claims description 26
- 210000002700 urine Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 230000001900 immune effect Effects 0.000 claims description 5
- 239000013642 negative control Substances 0.000 claims description 5
- 238000001917 fluorescence detection Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- WIUGGJKHYQIGNH-UHFFFAOYSA-N coproporphyrinogen I Chemical compound C1C(=C(C=2C)CCC(O)=O)NC=2CC(=C(C=2C)CCC(O)=O)NC=2CC(N2)=C(CCC(O)=O)C(C)=C2CC2=C(CCC(O)=O)C(C)=C1N2 WIUGGJKHYQIGNH-UHFFFAOYSA-N 0.000 claims 12
- 238000002562 urinalysis Methods 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- VORBHEGMEBOMMB-UHFFFAOYSA-N coproporphyrin i Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(CCC(O)=O)C(=C4)N3)C)=N2)C)=C(CCC(O)=O)C(C)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 VORBHEGMEBOMMB-UHFFFAOYSA-N 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 150000004032 porphyrins Chemical class 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 150000003278 haem Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- XNBNKCLBGTWWSD-UHFFFAOYSA-N 3-[8,13,18-tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,24-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(=C(CCC(O)=O)C(=C4)N=3)C)N2)CCC(O)=O)=C(CCC(O)=O)C(C)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 XNBNKCLBGTWWSD-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZXKIFUWANBZSKF-UHFFFAOYSA-N [I].CC(O)=O Chemical compound [I].CC(O)=O ZXKIFUWANBZSKF-UHFFFAOYSA-N 0.000 description 2
- 229960002749 aminolevulinic acid Drugs 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DAFUFNRZWDWXJP-UHFFFAOYSA-N uroporphyrin i Chemical compound N1C(C=C2C(=C(CC(O)=O)C(C=C3C(=C(CC(O)=O)C(=C4)N3)CCC(O)=O)=N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 DAFUFNRZWDWXJP-UHFFFAOYSA-N 0.000 description 2
- VZVFNUAIRVUCEW-UHFFFAOYSA-N uroporphyrin iii Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(CCC(O)=O)C(=C4)N3)CC(O)=O)=N2)CC(O)=O)=C(CCC(O)=O)C(CC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 VZVFNUAIRVUCEW-UHFFFAOYSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- BYHCARMYTOPDGI-UHFFFAOYSA-N 23H-porphyrin-2,3,5,7,8,10,21-heptacarboxylic acid Chemical compound N1C(C=C2N=C(C=C3N(C(=C4C(O)=O)C(C(O)=O)=C3C(O)=O)C(O)=O)C=C2)=CC=C1C(C(O)=O)=C1C(C(=O)O)=C(C(O)=O)C4=N1 BYHCARMYTOPDGI-UHFFFAOYSA-N 0.000 description 1
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 description 1
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 description 1
- OOOQNKMJLOLMHC-UHFFFAOYSA-N 5-[[3,4-diethyl-5-[[5-formyl-3-(3-hydroxypropyl)-4-methyl-1h-pyrrol-2-yl]methyl]-1h-pyrrol-2-yl]methyl]-4-(3-hydroxypropyl)-3-methyl-1h-pyrrole-2-carbaldehyde Chemical compound N1C(CC2=C(C(C)=C(C=O)N2)CCCO)=C(CC)C(CC)=C1CC=1NC(C=O)=C(C)C=1CCCO OOOQNKMJLOLMHC-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- -1 Ruporphyrin I Chemical class 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940043215 aminolevulinate Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002449 erythroblastic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000008220 erythropoietic protoporphyria Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- UXXBQPAQUFNNGY-UHFFFAOYSA-N heptacarboxylporphyrin iii Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(C)=C(CCC(O)=O)C(N3)=C3)=N2)CCC(O)=O)=C(CCC(O)=O)C(CC(O)=O)=C1C=C1C(CCC(O)=O)=C(CC(O)=O)C3=N1 UXXBQPAQUFNNGY-UHFFFAOYSA-N 0.000 description 1
- AFHLWIUSJBEMJE-UHFFFAOYSA-N hexacarboxylporphyrin i Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(CCC(O)=O)C(=C4)N3)CC(O)=O)=N2)CC(O)=O)=C(CCC(O)=O)C(C)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AFHLWIUSJBEMJE-UHFFFAOYSA-N 0.000 description 1
- NTILFDFSYFWZAA-UHFFFAOYSA-N hexacarboxylporphyrin iii Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(C)=C(CCC(O)=O)C(N3)=C3)=N2)CC(O)=O)=C(CCC(O)=O)C(C)=C1C=C1C(CC(O)=O)=C(CCC(O)=O)C3=N1 NTILFDFSYFWZAA-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- UHKZSWAPQUEURH-UHFFFAOYSA-N isocoproporphyrin Chemical compound N1C(C=C2C(=C(C)C(C=C3C(CC)=C(C)C(N3)=C3)=N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C3=N1 UHKZSWAPQUEURH-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- RKGGYZGVLDHHRR-UHFFFAOYSA-N pentacarboxyporphyrin iii Chemical compound N1C(C=C2C(=C(CCC(=O)OC)C(C=C3C(=C(CCC(=O)OC)C(=C4)N3)CC(=O)OC)=N2)C)=C(CCC(=O)OC)C(C)=C1C=C1C(C)=C(CCC(=O)OC)C4=N1 RKGGYZGVLDHHRR-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
ポルフィリン類の標準溶液としては以下の試薬を使用した。すなわち、ウロポルフィリンI(以下、UroIと略),及びコプロポルフィリンI(以下、CoproIと略)は、Porphyrin Acid Chromatographic Marker kit(Porphyrin Products社製)に備えられている試薬を使用した。ウロポルフィリンIII(以下、UroIIIと略)及びコプロポルフィリンIII(以下、CoproIIIと略)は、Frontier Scientific, Inc.より購入した。アセトニトリルはHPLC用、その他はすべて試薬特級品を使用した。
ヒト健常人12人と膀胱がん患者31人の尿を各0.2mL採取し、被検尿試料とした。被検尿試料200μLに0.08%ヨウ素−酢酸混合溶液(1/1,V/V)を200μL添加し、ボルテックスで混合後、15000rpmで5分間遠心した。遠心後、上清を採取し、各40μLをHPLC機器に注入した。システムはShimadzu LC-10A VP(カラムはShiseido CAPCELL PAK C18 AG120、検出器はRF-10AXL蛍光検出器(Ex.406nm、Em.609nm))を用いた。移動相はA液:12.5%アセトニトリル・1M酢酸アンモニウム混合液(pH5.15)、B液:80%アセトニトリル・50mM酢酸アンモニウム混合液(pH5.15)を用い、A液で5分間holdし、A/B(100/0)−A/B(65/35)35分Linearグラジェント、A/B(65/35)−A/B(0/100)1分Linearグラジェント、B液で9分間holdし、A/B(0/100)−A/B(100/0)1分Linearグラジェント、A液で9分間holdした。測定は、流速1.0ml/min、温度40℃で行った。各被検尿試料を測定し、各ポルフィリン類の標準溶液のピーク面積から各試料の濃度を算出した。
がん患者(31例)と健常人(12例)のUroI、UroIII、CoproI、CoproIIIを測定した結果、CoproIの量が、陰性対照正常者尿試料中に存在するCoproIの量よりも高く、有意確率(両側)が0.004であって、0.05以下であったので、有意差があることを確認することができた(表1参照)。すなわち、CoproIを測定することにより、尿路系腫瘍患者と健常人とを明確に分けることが可能となり、尿中のCoproI(コプロポルフィリンI)が50.903nmol/gCRE以上である被検者は、腫瘍を有している危険性が高いと判定することができる。
Claims (6)
- 被検尿試料中のコプロポルフィリンIの検出手段を有し、(i)被検尿試料中に存在するコプロポルフィリンIの検出量が、陰性対照正常者尿試料中に存在するコプロポルフィリンIの検出量よりも有意に高い場合は、被検尿試料を採取した被検者が尿路系腫瘍患者であると判定し、(ii)被検尿試料中に存在するコプロポルフィリンIの検出量が、陽性対照尿路系腫瘍患者尿試料中に存在する、コプロポルフィリンIの検出量よりも有意に低い場合は、被検尿試料を採取した被検者が正常者であると判定することを特徴とする尿路系腫瘍の判定システム。
- 尿路系腫瘍が、膀胱がん、前立腺がん、腎臓がん、又は尿路上皮がんであることを特徴とする請求項1記載の判定システム。
- コプロポルフィリンIの検出手段が、HPLC蛍光検出手段又は免疫学的測定手段であることを特徴とする請求項1又は2記載の判定システム。
- 被検尿試料中のコプロポルフィリンIを検出し、(i)被検尿試料中に存在するコプロポルフィリンIの検出量が、陰性対照正常者尿試料中に存在するコプロポルフィリンIの検出量よりも有意に高い場合は、被検尿試料を採取した被検者が尿路系腫瘍患者であると判定し、(ii)被検尿試料中に存在するコプロポルフィリンIの検出量が、陽性対照尿路系腫瘍患者尿試料中に存在する、コプロポルフィリンIの検出量よりも有意に低い場合は、被検尿試料を採取した被検者が正常者であると判定することを特徴とする尿路系腫瘍の判定方法。
- 尿路系腫瘍が、膀胱がん、前立腺がん、腎臓がん、又は尿路上皮がんであることを特徴とする請求項4記載の判定方法。
- HPLC蛍光検出手段又は免疫学的測定手段を用いて、コプロポルフィリンIを測定することを特徴とする請求項4又は5記載の判定方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009129695A JP5224536B2 (ja) | 2009-05-28 | 2009-05-28 | 尿路系腫瘍の判定システム |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009129695A JP5224536B2 (ja) | 2009-05-28 | 2009-05-28 | 尿路系腫瘍の判定システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010276484A JP2010276484A (ja) | 2010-12-09 |
JP5224536B2 true JP5224536B2 (ja) | 2013-07-03 |
Family
ID=43423583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009129695A Active JP5224536B2 (ja) | 2009-05-28 | 2009-05-28 | 尿路系腫瘍の判定システム |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5224536B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127917B2 (ja) | 2010-12-13 | 2013-01-23 | 日立オートモティブシステムズ株式会社 | 車両制御装置 |
CN116818958B (zh) * | 2023-08-24 | 2023-11-21 | 北京挑战生物技术有限公司 | 一种发酵液中5-氨基乙酰丙酸和甘氨酸含量的测定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2657345B2 (ja) * | 1992-04-17 | 1997-09-24 | 新日本製鐵株式会社 | 医療用診断装置および疾患判断方法 |
JP5034032B2 (ja) * | 2004-09-29 | 2012-09-26 | Sbiファーマ株式会社 | 腫瘍診断剤 |
JP2006284298A (ja) * | 2005-03-31 | 2006-10-19 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 大腸腫瘍の診断方法 |
-
2009
- 2009-05-28 JP JP2009129695A patent/JP5224536B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010276484A (ja) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Fluorescence imaging of pathophysiological microenvironments | |
Sturm et al. | Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results | |
CN102735752B (zh) | 基于金纳米簇的肿瘤靶向活体多模态成像方法 | |
EP2150586B1 (en) | Dyes having ratiometric fluorescence response for detecting metabolites | |
CN102279270B (zh) | 利用聚集诱导发光监测β淀粉样蛋白聚集过程的方法 | |
US20060147379A1 (en) | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | |
Usama et al. | Hows and whys of tumor-seeking dyes | |
CN108051584B (zh) | 非结合胆红素的荧光探针的开发和应用 | |
Dey et al. | Renal clearable new NIR PRobe: Precise quantification of albumin in biofluids and fatty liver disease state identification through tissue specific high contrast imaging in vivo | |
Si et al. | Carboxylate-containing two-photon probe for the simultaneous detection of extra-and intracellular pH values in colon cancer tissue | |
Huang et al. | Light‐emitting agents for noninvasive assessment of kidney function | |
Reeßing et al. | A facile and reproducible synthesis of near-infrared fluorescent conjugates with small targeting molecules for microbial infection imaging | |
An et al. | First-in-Class: Cervical cancer diagnosis based on a urine test with fluorescent cysteine probe | |
JP5224536B2 (ja) | 尿路系腫瘍の判定システム | |
JP2024059621A (ja) | がんの診断及び治療のための組成物及び方法 | |
Li et al. | Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging | |
EP2842578B1 (en) | Diagnostic device for the detection of biomarkers | |
WO2010098435A1 (ja) | 癌転移部位検出方法、検出用キットおよびこれらを用いる癌の治療方法 | |
Ivanova-Radkevich et al. | Organization of clinical trials of photosensitizer based on 5-aminolevulinic acid hexyl ester | |
He et al. | A quinolinium-based dual-functional NIR fluorescent probe for the imaging of Aβ aggregation and mitochondrial pH | |
Salmon et al. | Europium labeled lactosylated albumin as a model workflow for the development of biotherapeutics | |
Ye et al. | Design a dual-response two-photon fluorescent probe for simultaneous imaging of mitochondrial viscosity and peroxynitrite in a thrombosis model | |
Wu et al. | Development and Evaluation of Targeted Optical Imaging Probes for Image‐Guided Surgery in Head and Neck Cancer | |
CN114874198B (zh) | 一种基于罗丹明-铜配合物的Aβ荧光探针及其应用 | |
US20160258871A1 (en) | Method of detecting bladder cancer by optical analysis of bodily fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120618 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130304 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130308 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5224536 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |